Skip to Main Content

Author Details

Nicholas G Nickols
University of California, Veteran Affairs Greater Los Angeles Healthcare System
2003
92
28
PMIDPaper TitleJournal TitlePublished Year
37802226Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADAR.Int J Radiat Oncol Biol Phys2024
35058580Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT.Prostate Cancer Prostatic Dis2023
37706534In Reply to "Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer".Oncologist2023
37647496Selecting the optimal radiation modality in prostate cancer.Clin Adv Hematol Oncol2023
37639648Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.J Clin Oncol2023
37084789Actionable Genomic Alterations in Prostate Cancer Among Black and White United States Veterans.Oncologist2023
37009941Quantitative assessment of PSMA PET response to therapy in castration-sensitive prostate cancer using an automated imaging platform for disease identification and measurement.Eur J Hybrid Imaging2023
36723856Multimodality Therapies for Localized Prostate Cancer.Curr Oncol Rep2023
36717727Mask R-CNN assisted 2.5D object detection pipeline of <sup>68</sup>Ga-PSMA-11 PET/CT-positive metastatic pelvic lymph node after radical prostatectomy from solely CT imaging.Sci Rep2023
36870853Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography.Eur Urol Oncol2023
36739178Early Safety and Efficacy Profile of Homogeneously Dosed Salvage Stereotactic Body Radiotherapy (SBRT) for Intraprostatic Recurrences After Low Dose Rate (LDR) Brachytherapy.Clin Genitourin Cancer2023
36797143Better Late than Never for Late Toxicity Assessment.Eur Urol2023
36633877Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.JAMA Oncol2023
36863416Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post Hoc Analysis of 3 Prospective Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Trials.Int J Radiat Oncol Biol Phys2023
36179990External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.Int J Radiat Oncol Biol Phys2023
36269935Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.J Clin Oncol2023
36007724Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial.Int J Radiat Oncol Biol Phys2023
34049980aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in <sup>18</sup>F-DCFPyL Images of Veterans with Prostate Cancer.J Nucl Med2022
35438754Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial.JAMA Netw Open2022
35469702High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.Eur Urol2022
35521072Prostate-Centric Versus Bony-Centric Registration in the Definitive Treatment of Node-Positive Prostate Cancer with Simultaneous Integrated Boost: A Dosimetric Comparison.Adv Radiat Oncol2022
35934601Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).Eur Urol2022
33602654Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.Eur Urol Oncol2022
35040965Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.JAMA Netw Open2022
35051385Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.Lancet Oncol2022
35050303Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.JAMA Oncol2022
34463809Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [<sup>18</sup>F]DCFPyL (PSMA) imaging for standardized reporting.Eur J Nucl Med Mol Imaging2022
34400799Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials.Prostate Cancer Prostatic Dis2022
34774650Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond.Radiother Oncol2022
31411981Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer.Eur Urol Oncol2021
33493615Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients.Int J Radiat Oncol Biol Phys2021
33637464Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review.Eur Urol Oncol2021
34902034Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.JAMA Netw Open2021
34964855Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis.JAMA Netw Open2021
34585025Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series.Adv Radiat Oncol2021
33962579Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.BMC Cancer2021
33985797Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.Eur Urol2021
34196715Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.JAMA Netw Open2021
33975579Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.BMC Cancer2021
34225789Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial.Trials2021
33309278A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER).Eur Urol2021
33219015High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors.Clin Cancer Res2021
33046413Prostate-specific Membrane Antigen Positron Emission Tomography-guided Radiotherapy.Eur Urol Focus2021
33386288Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome.Eur Urol Focus2021
33035622Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control.Radiother Oncol2021
32647353The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells.Prostate Cancer Prostatic Dis2021
30992160Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.Eur Urol2020
31924715Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study.J Nucl Med2020
31718822Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials.Eur Urol2020
33305100The Impact of <sup>18</sup>F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer.Adv Radiat Oncol2020
  • 1 - 50 of 92

Recommended Authors

Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Career Start Year 2013
Number of shared co-authors 18
Alan Dal Pra
University of Miami Miller School of Medicine
Career Start Year 2010
Number of shared co-authors 27
Xin Pei
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 4
Suneil Jain
Cancer Centre Belfast City Hospital, Queen's University Belfast
Career Start Year 2008
Number of shared co-authors 13
Arun A Azad
Peter MacCallum Cancer Centre
Career Start Year 2007
Number of shared co-authors 6
Nicholas van As
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Career Start Year 2005
Number of shared co-authors 6
Channing J Paller
Johns Hopkins University School of Medicine
Career Start Year 2004
Number of shared co-authors 29
Niven Mehra
Radboud university medical center
Career Start Year 2004
Number of shared co-authors 21
Neil B Desai
University of Texas Southwestern Medical Center
Career Start Year 2004
Number of shared co-authors 43
Scott T Tagawa
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Career Start Year 2003
Number of shared co-authors 24
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2001
Number of shared co-authors 22
Zhigang Zhang
Memorial Sloan Kettering Cancer Center
Career Start Year 2001
Number of shared co-authors 5
Emmanuel S Antonarakis
The Sidney Kimmel Cancer Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2000
Number of shared co-authors 60
Eleni Efstathiou
Houston Methodist Cancer Center
Career Start Year 2000
Number of shared co-authors 24
Michael J Morris
Memorial Sloan Kettering Cancer Center
Career Start Year 1999
Number of shared co-authors 35
Elisabeth I Heath
Karmanos Cancer Center, Wayne State University
Career Start Year 1999
Number of shared co-authors 30
Johann S de Bono
The Institute for Cancer Research
Career Start Year 1999
Number of shared co-authors 30
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Career Start Year 1998
Number of shared co-authors 11
Evan Y Yu
University of Washington and Fred Hutchinson Cancer Research Center
Career Start Year 1997
Number of shared co-authors 32
Inge M van Oort
Radboud University Medical Center
Career Start Year 1995
Number of shared co-authors 22
Michael A Carducci
Johns Hopkins School of Medicine
Career Start Year 1995
Number of shared co-authors 43
David I Quinn
USC Norris Comprehensive Cancer Center
Career Start Year 1993
Number of shared co-authors 13
Fred Saad
University of Montreal Health Center
Career Start Year 1990
Number of shared co-authors 40
Celestia S Higano
University of Washington and Fred Hutchinson Cancer Research Center
Career Start Year 1987
Number of shared co-authors 34
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 43
Maha Hussain
Northwestern University
Career Start Year 1984
Number of shared co-authors 36
Oliver Sartor
Tulane University School of Medicine
Career Start Year 1983
Number of shared co-authors 58
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Career Start Year 1981
Number of shared co-authors 47
Howard I Scher
Memorial Sloan Kettering Cancer Center
Career Start Year 1973
Number of shared co-authors 33
Alan Pollack
University of Miami Miller School of Medicine
Career Start Year 1963
Number of shared co-authors 60

Collaborators

Amar U Kishan
University of California los angeles
Co-authored papers 61
Michael L Steinberg
University of California los angeles
Co-authored papers 48
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 41
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 35
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 27
Patrick A Kupelian
university of california los angeles Medical Center
Co-authored papers 24
Christopher R King
University of California los angeles
Co-authored papers 19
Jeremie Calais
university of california los angeles
Co-authored papers 17
Tahmineh Romero
David Geffen School of Medicine at university of california los angeles
Co-authored papers 16
Minsong Cao
University of California Los Angeles
Co-authored papers 16
Ting Martin Ma
University of Washington
Co-authored papers 16
David Elashoff
David Geffen School of Medicine at University of California los angeles
Co-authored papers 16
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 15
Peter B Dervan
Co-authored papers 14
Nicholas G Zaorsky
University Hospitals Seidman Cancer Centre, Cleveland Medical Centre
Co-authored papers 13
Luca F Valle
University of California los angeles
Co-authored papers 13
David Jeffrey Demanes
University of California los angeles
Co-authored papers 11
Jesus E Juarez
University of California Los Angeles
Co-authored papers 11
Phuoc T Tran
University of Maryland School of Medicine
Co-authored papers 11
Johannes Czernin
university of california los angeles
Co-authored papers 11
Paul C Boutros
University of California los angeles
Co-authored papers 11
David Shabsovich
university of california los angeles Medical Center
Co-authored papers 11
Eric M Horwitz
Fox Chase Cancer Center
Co-authored papers 10
Fang-I Chu
David Geffen School of Medicine, University of California los angeles
Co-authored papers 10
Chandana A Reddy
Cleveland Clinic
Co-authored papers 9
Richard G Stock
Icahn School of Medicine at Mount Sinai
Co-authored papers 9
Paul L Nguyen
Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
Co-authored papers 9
Thomas M Pisansky
Mayo Clinic
Co-authored papers 9
Robert T Dess
University of Michigan ann arbor
Co-authored papers 9
Curtiland Deville
Johns Hopkins University
Co-authored papers 9
Release 1.2